As Lung Cancer Awareness Month comes to a close, Genelux remains committed to advancing potential new therapies for lung cancer. We’re focused on bringing hope to patients affected by both Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) through our ongoing clinical trials. To learn more about our active trials and how we’re working to make a difference, please visit our listings at https://lnkd.in/ezP8Yz3s. #LungCancerAwareness #Genelux #ClinicalTrials #LungCancerResearch #NSCLC #SCLC
关于我们
Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology company focused on improving the lives of patients affected by difficult-to-treat solid tumors. Our ChoiceTM Discovery Platform is the foundation of our oncolytic immunotherapy development, having produced over 500 different versions of the vaccinia virus. Olvi-Vec, our lead product candidate is currently in a Phase 3 registrational clinical trial for Platinum-Resistant/Refractory Ovarian Cancer (PRROC). Olvi-Vec is also being developed in Non-Small Cell Lung Cancer (NSCLC), recurrent Small Cell Lung Cancer (SCLC), and recurrent Ovarian Cancer. We are dedicated to advancing a pipeline of next-generation oncolytic immunotherapies that deliver the full complement of tumor neo-antigens with the power to stimulate a personalized immune response for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Information about our investigational products and clinical trials can be found here. For more information, please visit https://genelux.com/ and follow us on Twitter @Genelux_Corp and Facebook @Genelux. Olvi-Vec is an investigational product candidate not yet approved by the US Food and Drug Administration.
- 网站
-
https://genelux.com/
Genelux的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Westlake Village，California
- 类型
- 上市公司
- 创立
- 2001
地点
-
主要
获取路线
US，California，Westlake Village
Genelux员工
动态
-
According to the National Institute of Health, only 16% of lung cancers are diagnosed at an early stage when they’re most treatable. During Lung Cancer Awareness Month, let’s work together to raise awareness about the importance of regular screenings, especially for high-risk groups, as well as the research behind new therapies to further treatment for those diagnosed with advanced disease. #CancerResearch #Stage4NeedsMore #Biotech #Cancer #DrugResearch #Nasdaq
-
-
Genelux is pleased to announce the publication of our latest article in Cure, reflecting our unwavering commitment to viewing everything through the patient’s perspective. We remain dedicated to advancing research, supporting patients, and continuing the fight against cancer. Read the full story here, https://loom.ly/otmsYuo. #OvarianCancer #BreastCancer #BreastCancerAwarenessMonth #TogetherWeCan
-
-
Genelux Corporation Reports Third Quarter 2024 Financial Results & Provides General Business Updates. Read the latest press release https://loom.ly/U3yal38 #OvarianCancer #CancerResearch #Stage4NeedsMore #Biotech #Cancer #DrugResearch #Nasdaq
-
-
This Lung Cancer Awareness Month, we’re proud to highlight the potential of Olvi-Vec in treating both small cell and non-small cell lung cancer. Our innovative oncolytic viral immunotherapy aims to harness the immune system’s power to potentially target and destroy cancer cells effectively. As we celebrate this month, we remain committed to advancing research and exploring new therapies that can make a difference for patients facing these challenging diagnoses. Together, let’s work towards a future with more effective treatment options and better outcomes! #LungCancerAwarenessMonth #OlviVec #CancerResearch #Genelux #Stage4NeedsMore
-
-
Genelux to participate in a Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference on Monday, November 11th at 1:30 PM ET. A webcast link for the Guggenheim Conference event will be available at https://loom.ly/vB6eStw.
-
-
Unlike local tumor delivery methods, systemic therapy is a convenient route of administration that works throughout the entire body. This approach harnesses the power of the immune system and circulates treatment to potentially reach metastasized cells that may be undetected. Systemic therapies can provide a more comprehensive attack on cancer, improving outcomes for patients with advanced or recurrent disease. As we continue to explore innovative strategies, including oncolytic virus therapies like Olvi-Vec, the goal is to enhance the effectiveness and precision of treatments. Together, we can pave the way for a future where cancer care is more effective and personalized! #CancerTreatment #SystemicTherapy #InnovativeResearch #Genelux
-
We are excited to announce that the first patient has been dosed in our Phase 2 trial evaluating systemic therapy with Olvi-Vec in non-small cell lung cancer! "Today's milestone holds profound significance for patients with recurrent non-small cell lung cancer who face limited therapeutic options," said Thomas Zindrick, President, CEO and Chairman of Genelux. "This Phase 2 trial, in addition to our ongoing Phase 1b/2 trial evaluating intravenous delivered Olvi-Vec in patients with recurrent small cell lung cancer, co-sponsored with Newsoara Biopharma Co. Ltd., signifies the key advancement of Olvi-Vec to potentially be an important systemically administered oncolytic virus treatment option, setting the stage for the future of this promising field." To learn more: https://loom.ly/H_RaKZM #OlviVec #GNLX
-
Olvi-Vec's unique approach aims to harness the body’s immune system to fight tumors more effectively. Learn more about our mission to improve patient outcomes! https://loom.ly/GNMHays #OlviVec #OvarianCancer